Cargando…
ALK融合基因阳性非小细胞肺癌的研究进展
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug r...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136995/ https://www.ncbi.nlm.nih.gov/pubmed/30201071 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.10 |
| _version_ | 1783355095077879808 |
|---|---|
| collection | PubMed |
| description | The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work. |
| format | Online Article Text |
| id | pubmed-6136995 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-61369952018-10-03 ALK融合基因阳性非小细胞肺癌的研究进展 Zhongguo Fei Ai Za Zhi 综述 The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work. 中国肺癌杂志编辑部 2018-09-20 /pmc/articles/PMC6136995/ /pubmed/30201071 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.10 Text en 版权所有©《中国肺癌杂志》编辑部2018 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 综述 ALK融合基因阳性非小细胞肺癌的研究进展 |
| title | ALK融合基因阳性非小细胞肺癌的研究进展 |
| title_full | ALK融合基因阳性非小细胞肺癌的研究进展 |
| title_fullStr | ALK融合基因阳性非小细胞肺癌的研究进展 |
| title_full_unstemmed | ALK融合基因阳性非小细胞肺癌的研究进展 |
| title_short | ALK融合基因阳性非小细胞肺癌的研究进展 |
| title_sort | alk融合基因阳性非小细胞肺癌的研究进展 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136995/ https://www.ncbi.nlm.nih.gov/pubmed/30201071 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.09.10 |
| work_keys_str_mv | AT alkrónghéjīyīnyángxìngfēixiǎoxìbāofèiáideyánjiūjìnzhǎn AT alkrónghéjīyīnyángxìngfēixiǎoxìbāofèiáideyánjiūjìnzhǎn AT alkrónghéjīyīnyángxìngfēixiǎoxìbāofèiáideyánjiūjìnzhǎn |